Abstract
Summary
Small studies have previously suggested that sarcoidosis may be associated with low bone mineral density. In this observational study of 64 patients with sarcoidosis, bone mineral density was within the normal range at baseline, and there was no evidence of accelerated bone loss over 1–2 years.
Introduction
Several small studies have suggested that sarcoidosis may be associated with low bone mineral density (BMD).
Methods
We undertook a cross-sectional study of BMD in 64 patients with sarcoidosis. Of these, 27 with 25-hydroxyvitamin D <50 nmol/L entered a 1-year intervention study of vitamin D supplements, and 37 entered a 2-year longitudinal study of BMD, with the primary endpoint of the change in lumbar spine BMD.
Results
The mean age of participants was 58 years, 68 % were female, and 8 % were currently using oral glucocorticoids. At baseline, BMD for the entire cohort was greater than the expected values for the population at the lumbar spine (mean Z-score 0.7, P < 0.001) and total body (0.5, P < 0.001) and similar to expected values at the femoral neck (0.2, P = 0.14) and total hip (0.2, P = 0.14). BMD did not change at any of these four sites (P > 0.19) over 2 years in the longitudinal study. In the intervention study, vitamin D supplements had no effect on BMD, and therefore we pooled the data from all participants. BMD did not change over 1 year at the spine, total hip, or femoral neck (P > 0.3), but decreased by 0.7 % (95 % confidence interval 0.3–1.1) at the total body (P = 0.019).
Conclusions
BMD was normal at baseline, and there was no consistent evidence of accelerated bone loss over 1–2 years, regardless of baseline vitamin D status. Patients with sarcoidosis not using oral glucocorticoids do not need routine monitoring of BMD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Montemurro L, Fraioli P, Rizzato G (1991) Bone loss in untreated longstanding sarcoidosis. Sarcoidosis 8:29–34
Rottoli P, Gonnelli S, Silitro S et al (1993) Alterations in calcium metabolism and bone mineral density in relation to the activity of sarcoidosis. Sarcoidosis 10:161–162
Rizzato G (1998) Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax 53:425–429
Hamada K, Nagai S, Tsutsumi T et al (1999) Bone mineral density and vitamin D in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 16:219–223
Adler RA, Funkhouser HL, Petkov VI et al (2003) Glucocorticoid-induced osteoporosis in patients with sarcoidosis. Am J Med Sci 325:1–6
Sipahi S, Tuzun S, Ozaras R et al (2004) Bone mineral density in women with sarcoidosis. J Bone Miner Metab 22:48–52
Heijckmann AC, Huijberts MS, De Vries J et al (2007) Bone turnover and hip bone mineral density in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 24:51–58
Heijckmann AC, Drent M, Dumitrescu B et al (2008) Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study. Osteoporos Int 19:839–847
Bolland MJ, Wilsher ML, Grey A et al (2013) Randomised controlled trial of vitamin D supplementation in sarcoidosis. BMJ Open 3:e003562
Angus RM, Sambrook PN, Pocock NA et al (1989) A simple method for assessing calcium intake in Caucasian women. J Am Diet Assoc 89:209–214
Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477–501
Burke RR, Rybicki BA, Rao DS (2010) Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med 31:474–484
Sharma OP (2010) Vitamin D and sarcoidosis. Curr Opin Pulm Med 16:487–488
Sage RJ, Rao DS, Burke RR et al (2011) Preventing vitamin D toxicity in patients with sarcoidosis. J Am Acad Dermatol 64:795–796
Sweiss NJ, Lower EE, Korsten P et al (2011) Bone health issues in sarcoidosis. Curr Rheumatol Rep 13:265–272
Sharma OP (1996) Vitamin D, calcium, and sarcoidosis. Chest 109:535–539
Conron M, Young C, Beynon HL (2000) Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology (Oxford) 39:707–713
Reid IR, Bolland MJ, Grey A (2014) Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 383:146–155
Avenell A, Gillespie WJ, Gillespie LD et al (2009) Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2:CD000227
DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group (2010) Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 340:b5463
Funding
This study was funded by the Health Research Council of New Zealand and the Greenlane Research and Education Fund.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Trial registration: This trial is registered at the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au). The registration number is ACTRN12607000364471, date of registration July 5, 2007.
Rights and permissions
About this article
Cite this article
Bolland, M.J., Wilsher, M.L., Grey, A. et al. Bone density is normal and does not change over 2 years in sarcoidosis. Osteoporos Int 26, 611–616 (2015). https://doi.org/10.1007/s00198-014-2870-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-014-2870-7